| Identification | Back Directory | [Name]
Baicalin-7-diglucoside | [CAS]
114482-86-9 | [Synonyms]
Oroxin B
Oroxin B >=98% (HPLC)
Baicalin-7-diglucoside
Baicalein 7-diglucoside
Baicalein 7-O-diglucoside
Baicalein-7-O-gentiobioside
Baicalein 7-O-beta-gentiobioside
Baicalein-7-O-diglucoside (Oroxin B)
Oroxin B, 98%, from Oroxylum indicum
5,6-Dihydroxy-4-oxo-2-phenyl-4H-chromen-7-yl6-O-β-D-glucopyranosyl-β-D-glucopyranoside
5,6-Dihydroxy-4-oxo-2-phenyl-4H-chromen-7-yl 6-O-β-D-glucopyranos yl-β-D-glucopyranoside
4H-1-Benzopyran-4-one,7-[(6-O-b-D-glucopyranosyl-b-D-glucopyranosyl)oxy]-5,6-dihydroxy-2-phenyl-
4H-1-Benzopyran-4-one, 7-[(6-O-β-D-glucopyranosyl-β-D-glucopyranosyl)oxy]-5,6-dihydroxy-2-phenyl-
7-[(6-O-beta-D-Glucopyranosyl-beta-D-glucopyranosyl)oxy]-5,6-dihydroxy-2-phenyl-4H-1-benzopyran-4-one | [Molecular Formula]
C27H30O15 | [MDL Number]
MFCD22125002 | [MOL File]
114482-86-9.mol | [Molecular Weight]
594.52 |
| Chemical Properties | Back Directory | [Boiling point ]
957.5±65.0 °C(Predicted) | [density ]
1.76 | [storage temp. ]
4°C, protect from light | [solubility ]
Soluble in methanol and water | [form ]
powder | [pka]
5.91±0.40(Predicted) | [color ]
Yellowish |
| Hazard Information | Back Directory | [Uses]
Oroxin B is a component of the seed of O. (oroxylum) indicum and is used in traditional Chinese medicine for antiinflammatory, analgesic and other functions. It also has been observed to selectively induce tumor-suppressive ER stress and inhibits tumor-adaptive ER stress in B-lymphoma cells attenuating tumor growth. | [in vivo]
Oroxin B (30 mg/kg, i.p., 28 days) induces malignant lymphoma cell ER stress, and inhibits tumor growth in human lymphoma cell (Raji cell) xenograft model[2].
Oroxin B (160 μM of 10 μL, injected into the knee joints of mice) protects articular cartilage in destabilized medial meniscus (DMM) induced mice OA[3].
Oroxin B (200 mg/kg/day, oral gavage) relieves hepatic inflammation and inhibits MAFLD progression in HFD-fed rats[4].
| Animal Model: | Human lymphoma cell (Raji cell) xenograft model[2] | | Dosage: | 30 mg/kg | | Administration: | i.p., 28 days | | Result: | Induced malignant lymphoma cell ER stress.
Inhibited tumor growth.
Prolonged overall survival of tumor-bearing mice. |
| Animal Model: | HFD-fed rats[4] | | Dosage: | 200 mg/kg/day | | Administration: | oral gavage | | Result: | Reduced the levels of plasma lipids, LPS, IL-6, and TNF-α.
Inhibited liver fibrosis by reducing collagen deposition.
|
| [storage]
4°C, protect from light |
|
|